🇺🇸 FDA
Pipeline program

0.9% sodium chloride, Lepodisiran

J3L-MC-EZEF

Phase 3 small_molecule active

Quick answer

0.9% sodium chloride, Lepodisiran for Atherosclerotic Cardiovascular Disease Elevated lp(a) is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).

Program details

Company
Eli Lilly Co.
Indication
Atherosclerotic Cardiovascular Disease Elevated lp(a)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials